Orodispersible Tablets (ODTs) are solid unit dosage forms that disintegrate or dissolve rapidly in the mouth without chewing and without the need for water. The demand for this dosage form has been increasing, especially in pediatric and geriatric patient populations who find swallowing conventional tablets difficult or uncomfortable.
ODTs are formulated from various excipients, including binders and disintegrants. The most common binders are methacrylic acid copolymers, which have high internal strength to support the formulation of high dose drugs. They also have the property of water resistance and are less sensitive to moisture than standard tablet formulations. The most popular disintegrants are mannitol and aspartame.
Increasing geriatric population across the globe is anticipated to drive growth of the global orodispersible tablets market. Elderly people prefer self-administration of medications for easy accessibility and convenience. Rising focus on healthcare facilities for the elderly also boosts the market.
However, increased pricing pressure is projected to hinder growth of the global orodispersible tablets market in the coming years.
- This report provides in-depth analysis of the global orodispersible tabletsmarket, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global orodispersible tabletsmarket based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global orodispersible tabletsmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global orodispersible tabletsmarket
-
-
- Analgesics
- Antiemetics
- Antipsychotics
- Anti-inflammatory Drugs
- Sedatives/Hypnotics
- Antihypertensives
- Others
-
-
- Central Nervous System Disorders
- Gastrointestinal Disorders
- Cardiovascular Disorders
- Respiratory Disorders
- Allergy and Asthma
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
-
- Pediatric Patients
- Adult Patients
- Geriatric Patients
-
-
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
-
-
- Lyophilization
- Tablet Molding
- Spray Drying
- Sublimation
- Others
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
-
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis International AG
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Cipla Limited
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Torrent Pharmaceuticals Ltd.
- F. Hoffmann-La Roche Ltd.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
